U.S. markets open in 8 hours 51 minutes

BGI Genomics Co., Ltd. (300676.SZ)

Shenzhen - Shenzhen Delayed Price. Currency in CNY
Add to watchlist
109.08-3.42 (-3.04%)
As of 12:23PM CST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close112.50
Bid109.08 x 0
Ask109.20 x 0
Day's Range108.33 - 112.80
52 Week Range95.88 - 180.00
Avg. Volume3,995,716
Market Cap45.15B
Beta (5Y Monthly)0.57
PE Ratio (TTM)17.69
EPS (TTM)6.17
Earnings DateAug 25, 2021 - Aug 30, 2021
Forward Dividend & Yield0.35 (0.29%)
Ex-Dividend DateJul 07, 2021
1y Target Est100.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      BGI Statement in Response to Reuters Report

      BGI is aware of reports in Reuters regarding the company's non-invasive prenatal test (NIPT test) - NIFTY (Non-Invasive Fetal TrisomY).

    • PR Newswire

      Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

      Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd., (300676.SZ), one of the world's leading genomics companies, today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China.

    • Reuters

      Chinese state fund invests in gene firm BGI

      The Chinese government has made an investment in BGI Genomics Co, a listed Chinese company that has supplied millions of COVID-19 tests globally as the gene firm seeks to fund exponential growth driven by the pandemic. BGI Group, which runs a massive gene databank in China and has DNA sequencing contracts with health firms and universities worldwide, has in the past responded to claims from U.S. security agencies that it is closely linked to the Chinese government by saying it has no Chinese government capital. BGI Genomics, the company's subsidiary listed on the Shenzhen stock exchange, raised the equivalent of just over $300 million in a private placement to investors including China's biggest state investment vehicle, the State Development and Investment Corp (SDIC), filings to the exchange on Feb. 1 show.